Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Laura Orsolini, Virginio Salvi & Umberto Volpe. (2022) Craving and addictive potential of esketamine as side effects?. Expert Opinion on Drug Safety 21:6, pages 803-812.
Read now
Read now
Jacques Le Houezec & Henri-Jean Aubin. (2013) Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. Expert Opinion on Pharmacotherapy 14:14, pages 1959-1967.
Read now
Read now
Kenneth M. Carpenter, David McDowell, Daniel J. Brooks, Wendy Y. Cheng & Frances R. Levin. (2009) A Preliminary Trial: Double-Blind Comparison of Nefazodone, Bupropion-SR, and Placebo in the Treatment of Cannabis Dependence. American Journal on Addictions 18:1, pages 53-64.
Read now
Read now
Articles from other publishers (36)
Kathleen R. McNealy, Lucas Weyrich & Rick A. Bevins. (2023) The co-use of nicotine and prescription psychostimulants: A review of their behavioral and neuropharmacological interactions. Drug and Alcohol Dependence 248, pages 109906.
Crossref
Crossref
Jed E. Rose, Perry N. Willette, Tanaia L. Botts, David R. Botts & Frederique M. Behm. (2022) Bupropion/zonisamide combination to assist smokers to switch from combustible cigarettes to electronic nicotine delivery systems (ENDS). Drug and Alcohol Dependence 234, pages 109346.
Crossref
Crossref
Ranjithkumar Chellian, Azin Behnood-Rod, Dawn M Bruijnzeel, Ryann Wilson, Vijayapandi Pandy & Adriaan W Bruijnzeel. (2021) Rodent models for nicotine withdrawal. Journal of Psychopharmacology 35:10, pages 1169-1187.
Crossref
Crossref
Lauren C. Smith, Lani Tieu, Raymond T. Suhandynata, Brent Boomhower, Melissa Hoffman, Yadira Sepulveda, Lieselot L. G. Carrette, Jeremiah D. Momper, Robert L. Fitzgerald, Kate Hanham, Joseph Dowling, Marsida Kallupi & Olivier George. (2021) Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats. Psychopharmacology 238:8, pages 2201-2211.
Crossref
Crossref
Changbae Lee, Sang Cheol Lee, Yeon Seob Shin, Sangwoo Park, Ki Bum Won, Soe Hee Ann & Eun Jae Ko. (2020) Severity, Progress, and Related Factors of Mood Disorders in Patients with Coronary Artery Disease: A Retrospective Study. Healthcare 8:4, pages 568.
Crossref
Crossref
Greer McKendrick, Sonakshi Sharma, Dongxiao Sun, Patrick A. Randall & Nicholas M. Graziane. (2020) Acute and chronic bupropion treatment does not prevent morphine-induced conditioned place preference in mice. European Journal of Pharmacology 889, pages 173638.
Crossref
Crossref
Jeffrey M. Engelmann, Maher Karam-Hage, Vance A. Rabius, Jason D. Robinson & Paul M. Cinciripini. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
399
410.e5
.
Yumiko Ikeda, Takuya Funayama, Amane Tateno, Haruhisa Fukayama, Yoshiro Okubo & Hidenori Suzuki. (2019) Bupropion increases activation in nucleus accumbens during anticipation of monetary reward. Psychopharmacology 236:12, pages 3655-3665.
Crossref
Crossref
Asti Jackson, Deniz Bagdas, Pretal P. Muldoon, Aron H. Lichtman, F. Ivy Carroll, Mark Greenwald, Michael F. Miles & M. Imad Damaj. (2017) In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. Neuropharmacology 118, pages 38-45.
Crossref
Crossref
ME Mooney, JM Schmitz, S Allen, J Grabowski, P Pentel, A Oliver & DK Hatsukami. (2016) Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial. Clinical Pharmacology & Therapeutics 100:4, pages 344-352.
Crossref
Crossref
Debasish Basu, Sukanya Mitra & Nalini Vadivelu. 2015. Substance Abuse. Substance Abuse
89
107
.
Maher Karam-Hage, Paul M. Cinciripini & Ellen R. Gritz. (2014) Tobacco use and cessation for cancer survivors: An overview for clinicians. CA: A Cancer Journal for Clinicians 64:4, pages 272-290.
Crossref
Crossref
Aryeh I HermanElise E DeVito, Kevin P Jensen & Mehmet Sofuoglu. (2014) Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics 15:2, pages 221-234.
Crossref
Crossref
Henri-Jean Aubin, Amandine Luquiens & Ivan Berlin. (2014) Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. British Journal of Clinical Pharmacology 77:2, pages 324-336.
Crossref
Crossref
Maher Karam-Hage, Vance Rabius, Paul M. Cinciripini, Jason D. Robinson & Ellen R. Gritz. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
360
371.e5
.
Paraschiva Postolache, Doina-Clementina Cojocaru, Marian Olaru, Doina Todea & Roxana-Maria Nemes. (2013) Pharmacotherapy for smoking cessation - The experience of a smoking cessation center. Pharmacotherapy for smoking cessation - The experience of a smoking cessation center.
Mehmet Sofuoglu, Aryeh I. Herman, Yisheng Li & Andrew J. Waters. (2012) Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology 224:3, pages 413-420.
Crossref
Crossref
Abby M. Bailey & Tracy Macaulay. (2012) Pharmacologic Approaches to Smoking Cessation. Orthopedics 35:6, pages 505-511.
Crossref
Crossref
Andrew M. Busch, Belinda Borrelli & Adam M. Leventhal. (2011) The Relationship between Smoking and Depression Post-Acute Coronary Syndrome. Current Cardiovascular Risk Reports 5:6, pages 510-518.
Crossref
Crossref
David Kalman, Lawrence Herz, Peter Monti, Christopher W. Kahler, Marc Mooney, Stephanie Rodrigues & Kathryn O’Connor. (2011) Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: Results from a randomized, double-blind, placebo-controlled study. Drug and Alcohol Dependence 118:2-3, pages 111-118.
Crossref
Crossref
M. Kotlyar, D. Drone, P. Thuras, D. K. Hatsukami, L. Brauer, D. E. Adson & M. al'Absi. (2011) Effect of Stress and Bupropion on Craving, Withdrawal Symptoms, and Mood in Smokers. Nicotine & Tobacco Research 13:6, pages 492-497.
Crossref
Crossref
Min-Hyuk KimSeongho Min. (2011) Craving and treatment in smoking. Journal of the Korean Medical Association 54:4, pages 401.
Crossref
Crossref
Aryeh I. Herman & Mehmet Sofuoglu. (2010) Comparison of Available Treatments for Tobacco Addiction. Current Psychiatry Reports 12:5, pages 433-440.
Crossref
Crossref
F. Ivy Carroll, Bruce E. Blough, S. Wayne Mascarella, Hernán A. Navarro, J. Brek Eaton, Ronald J. Lukas & M. Imad Damaj. (2010) Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking Cessation. Journal of Medicinal Chemistry 53:5, pages 2204-2214.
Crossref
Crossref
Maher Karam-Hage, Jennifer Minnix & Paul M. Cinciripini. 2011. Addiction Medicine. Addiction Medicine
417
443
.
Andrew J. Kwilasz, Louis S. Harris & Robert E. Vann. (2009) Removal of continuous nicotine infusion produces somatic but not behavioral signs of withdrawal in mice. Pharmacology Biochemistry and Behavior 94:1, pages 114-118.
Crossref
Crossref
Teresa R. Franklin, Derek Harper, Kyle Kampman, Susan Kildea-McCrea, Will Jens, Kevin G. Lynch, Charles P. O’Brien & Anna Rose Childress. (2009) The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug and Alcohol Dependence 103:1-2, pages 30-36.
Crossref
Crossref
Jennifer W. Tidey & Damaris J. Rohsenow. (2009) Intention to quit moderates the effect of bupropion on smoking urge. Nicotine & Tobacco Research 11:3, pages 308-312.
Crossref
Crossref
Laura E. O'Dell & Taline V. Khroyan. (2009) Rodent models of nicotine reward: What do they tell us about tobacco abuse in humans?. Pharmacology Biochemistry and Behavior 91:4, pages 481-488.
Crossref
Crossref
Jed E. Rose. (2008) Disrupting Nicotine Reinforcement. Annals of the New York Academy of Sciences 1141:1, pages 233-256.
Crossref
Crossref
David V. Conti, Won Lee, Dalin Li, Jinghua Liu, David Van Den Berg, Paul D. Thomas, Andrew W. Bergen, Gary E. Swan, Rachel F. Tyndale, Neal L. Benowitz & Caryn Lerman. (2008) Nicotinic acetylcholine receptor β2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Human Molecular Genetics 17:18, pages 2834-2848.
Crossref
Crossref
Ashish Dhir & S.K. Kulkarni. (2008) Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor. Fundamental & Clinical Pharmacology 22:4, pages 387-394.
Crossref
Crossref
Giovanni W. Amarante, Patrícia Rezende, Mayra Cavallaro & Fernando Coelho. (2008) Acyloins from Morita–Baylis–Hillman adducts: an alternative approach to the racemic total synthesis of bupropion. Tetrahedron Letters 49:23, pages 3744-3748.
Crossref
Crossref
Brian Hitsman, James MacKillop, Anne Lingford-Hughes, Tim M. Williams, Faheem Ahmad, Sally Adams, David J. Nutt & Marcus R. Munafò. (2007) Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology 196:4, pages 611-621.
Crossref
Crossref
Ashish Dhir & S.K. Kulkarni. (2007) Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. European Journal of Pharmacology 568:1-3, pages 177-185.
Crossref
Crossref
Linda P. Dwoskin, Anthony S. Rauhut, Kelley A. King-Pospisil & Michael T. Bardo. (2006) Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent. CNS Drug Reviews 12:3-4, pages 178-207.
Crossref
Crossref